Aurobindo Pharma Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Press Release on Audited Financial Results for the quarter and year ended March 31, 2025".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma reported Q4 FY25 revenue of ₹8,382 Cr, up 10.6% YoY, and full-year FY25 revenue of ₹31,724 Cr, up 9.4% YoY — both all-time highs. US formulations grew 13.5% YoY to ₹4,072 Cr (USD 470M) driven by volume growth and new launches, while Europe surged 17.2% YoY to ₹2,147 Cr and ARV revenue jumped 29.4% YoY to ₹308 Cr; Growth Markets softened (-7.8% YoY to ₹786 Cr). EBITDA before R&D was ₹2,202 Cr in Q4 with a 26.3% margin, while FY25 EBITDA margin improved 73 bps to 25.7%. Net profit for Q4 stood at ₹903 Cr (EPS ₹15.56), with FY25 net profit rising 9.9% to ₹3,484 Cr. The company filed 9 ANDAs and received 5 final USFDA approvals in Q4, taking cumulative filings to 861 ANDAs and 690 final approvals.
Broad-based revenue growth, full-year margin expansion of 73 bps, and record-high sales support a positive read on the stock, with management flagging Europe nearing the $1 billion milestone as a key future catalyst. Growth Markets weakness is a minor watchpoint but is more than offset by strength in core US and Europe businesses.